Organon & Co.

Equities

OGN

US68622V1061

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-03-28 pm EDT 5-day change 1st Jan Change
18.8 USD +1.90% Intraday chart for Organon & Co. +3.58% +30.37%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Aurobindo Pharma Gets US FDA Final Nod for Mometasone Furoate Monohydrate Nasal Spray MT
Philips: new CFO in October CF
New York attorney general urges stronger safety warning on asthma drug Singulair RE
Organon's Hadlima Chosen by VA as Substitute for Humira MT
Goldman Sachs Adjusts Price Target on Organon to $18 From $16, Keeps Neutral Rating MT
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary CI
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary CI
Sector Update: Health Care Stocks Edge Higher Premarket Thursday MT
Organon's Q4 Adjusted Earnings, Revenue Rise; 2024 Revenue Guidance Issued MT
Transcript : Organon & Co., Q4 2023 Earnings Call, Feb 15, 2024
Organon & Co. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Earnings Flash (OGN) ORGANON & CO. Posts Q4 Revenue $1.6B, vs. Street Est of $1.48B MT
Earnings Flash (OGN) ORGANON & CO. Reports Q4 EPS $0.88, vs. Street Est of $0.83 MT
Organon & Co. Declares Quarterly Dividend, Payable on March 14, 2024 CI
Organon & Co. Provides Earnings Guidance for the Year 2024 CI
Organon Says Xaciato Vaginal Gel 2% Now Available in the US via Prescription to Treat Bacterial Vaginosis MT
Organon?S Xaciato (Clindamycin Phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis in Females Aged 12 and Older CI
Transcript : Organon & Co. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 01:30 PM
Organon Affirms 2023 Revenue Outlook, Sets 2024 Guidance; Shares Jump MT
Organon Signs Agreement With Eli Lilly to Distribute, Market Two Migraine Medicines in Europe MT
Organon & Co. and Eli Lilly and Company Enter Commercialization Agreement in Europe for Two Migraine Medicines CI
Organon & Co. Announces Departure of Sandra Milligan as Head of Research and Development Effective January 5, 2024 CI
Transcript : Organon & Co. Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-29-2023 11:00 AM
Piper Sandler Adjusts Organon & Co.'s Price Target to $22 From $32, Maintains Overweight Rating MT
Selecta Biosciences Merges With Cartesian Therapeutics MT
Chart Organon & Co.
More charts
Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and established brands. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. The Company’s Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, respiratory, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
18.8 USD
Average target price
21.38 USD
Spread / Average Target
+13.70%
Consensus
  1. Stock
  2. Equities
  3. Stock Organon & Co. - Nyse
  4. News Organon & Co.
  5. Goldman Sachs Adjusts Price Target for Organon & Co to $41 From $42, Maintains Buy Rating